|
WO2021067404A2
|
|
Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same
|
|
WO2021055669A1
|
|
Fc variants with reduced effector function
|
|
WO2020247932A1
|
|
Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use
|
|
WO2020247929A1
|
|
High affinity anti-cd3 antibodies, and methods for their generation and use
|
|
EP3695003A1
|
|
Anti-respiratory syncytial virus antibodies, methods of their generation and use
|
|
CN110913895A
|
|
anti-CD 3 binding domains and antibodies comprising the same and methods of making and using the same
|
|
WO2018152516A1
|
|
Proteins binding cd33, nkg2d and cd16
|
|
AU2018221172A1
|
|
Monoclonal antibodies and cocktails for treatment of Ebola infections
|
|
WO2018148447A1
|
|
Antibody heavy chain variable domains targeting the nkg2d receptor
|
|
WO2018148445A1
|
|
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
CN110035771A
|
|
Anti respiratory syncitial virus antibodies and its generation and application method
|
|
AU2017345786A1
|
|
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
WO2018075954A2
|
|
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
AU2017286432A1
|
|
Anti-coagulation factor XI antibodies
|
|
CA2982131A1
|
|
Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
|
|
AU2015201796A1
|
|
Rationally designed, synthetic antibody libraries and uses therefor
|
|
WO2015153765A1
|
|
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
|
US2016313345A1
|
|
Polyclonal mixtures of antibodies, and methods of making and using them
|
|
US2014323315A1
|
|
Polyspecificity reagents, methods for their preparation and use
|
|
US2014377269A1
|
|
Multivalent antibody analogs, and methods of their preparation and use
|
